Conversation with The Cancer Letter

Conversation with The Cancer Letter Free

Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it

Today’s critical shortage of cisplatin and carboplatin occurred because manufacturers failed to invest in enhancing production capacity, Richard Pazdur, director of the FDA Oncology Center of Excellence and acting director of the Office of Oncologic Diseases, said to The Cancer Letter.

May 30, 2023

Vol.49 No.22

By Paul Goldberg

Conversation with The Cancer Letter

ASCO’s Julie Gralow: At least 100,000 (and up to 500,000) cancer patients affected by cisplatin, carboplatin shortage

The shortage of platinum-based drugs in the United States is an endemic problem—i.e., Europe is unaffected—caused by the absence of transparency, dearth of early warnings, and a lack of redundancy in the supply chain.

May 26, 2023

Vol.49 No.21

By Paul Goldberg

Cancer History Project Conversation with The Cancer Letter

Karnofsky winner Hagop Kantarjian: We changed the course of leukemias from mostly incurable to mostly curable

Leukemia was mostly a fatal disease when Hagop Kantarjian, a medical student at the American University of Lebanon in Beirut, first came to MD Anderson in 1978.

May 26, 2023

Vol.49 No.21

By Jacquelyn Cobb

Conversation with The Cancer Letter

USPSTF’s Wanda Nicholson: Screening saves lives, but screening alone won’t fix disparities in cancer deaths

The U.S. Preventive Services Task Force’s latest draft recommendation on breast cancer screening is based in part on data on racial disparities in breast cancer mortality.

May 12, 2023

Vol.49 No.19

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Monica Bertagnolli’s Cancer Plan makes the most of her two roles: NCI director and leader of the National Cancer Program

This point is easily overlooked: Monica Bertagnolli has two jobs, not one. She is the director of the National Cancer Institute and head of the National Cancer Program.

April 14, 2023

Vol.49 No.15

By Paul Goldberg and Matthew Bin Han Ong

Conversation with The Cancer Letter Judiciary

Bipartisan Policy Center’s Anand Parekh: Rulings on USPSTF, mifepristone are ideological threats to evidence-based care

The United States has the worst health outcomes of any high-income nation—lagging behind on health status indicators including mortality, fertility, and morbidity—and recent rulings by Texas district judges against preventive services and mifepristone would widen that gap, experts say.

April 14, 2023

Vol.49 No.15

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Gary Schwartz talks about his vision for Case CCC, leaving New York, his illustrious father—and Isaac Asimov

For Gary Schwartz, leaving New York was the only difficult part of taking the top job at Case Comprehensive Cancer Center.

April 07, 2023

Vol.49 No.14

By Paul Goldberg

Conversation with The Cancer Letter

Harvard’s Carmel Shachar: Texas ruling that guts ACA preventive care likely to reach Supreme Court—and be upheld

In an era of judicial conservatism, a recent ruling that invalidates the Affordable Care Act’s preventive services mandate is likely to be upheld by higher courts, including the Supreme Court, legal experts say.

March 31, 2023

Vol.49 No.13

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it

ASCO’s Julie Gralow: At least 100,000 (and up to 500,000) cancer patients affected by cisplatin, carboplatin shortage

Karnofsky winner Hagop Kantarjian: We changed the course of leukemias from mostly incurable to mostly curable

USPSTF’s Wanda Nicholson: Screening saves lives, but screening alone won’t fix disparities in cancer deaths

Georgetown takes cancer screening, prevention to underserved DC neighborhoods

David Lauren: We’re focused on cancer. This isn’t about just sending a check. This is our mission.

Monica Bertagnolli’s Cancer Plan makes the most of her two roles: NCI director and leader of the National Cancer Program

Bipartisan Policy Center’s Anand Parekh: Rulings on USPSTF, mifepristone are ideological threats to evidence-based care

Gary Schwartz talks about his vision for Case CCC, leaving New York, his illustrious father—and Isaac Asimov

Harvard’s Carmel Shachar: Texas ruling that guts ACA preventive care likely to reach Supreme Court—and be upheld

Renew today!

Subscriber content

Never miss an issue!

Login